Influenza A Clinical Trial
— H7N9vax-1Official title:
An Open Label, Dose Escalation Phase I Trial to Assess Safety and Immunogenicity of the H7HLAII DNA Vaccine, Encoding Influenza Hemagglutinin H7 Directed to HLA Class II, for Prophylaxis of Pandemic Influenza Infection in Healthy Volunteers
The purpose of this study is to assess safety and immunogenicity of H7HLAII, a DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules, for prophylaxis of pandemic H7N9 influenza infection in healthy volunteers.
Status | Recruiting |
Enrollment | 27 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Healthy subjects, as concluded from the medical history, physical examination test including normal vital signs, and clinical judgment, without the need for medication. - For women with childbearing potential (WOCBP), defined as fertile following menarche and until becoming post-menopausal (i.e. no menses for 12 months without an alternative medical cause) unless permanently sterile by hysterectomy, bilateral salpingectomy and bilateral oophorectomy: Must use a highly effective contraceptive measures (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination), and a negative urine pregnancy test before administration of each dose of vaccine. Must agree to not donate eggs during the study and the first three months after their last study visit. - Able to understand and willing to sign the Informed Consent Form (ICF), which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. - Subjects able to understand and comply with the study protocol, including being able to attend the scheduled visits. Exclusion Criteria: - Medical Conditions 1. Ongoing or recent (< 2 weeks) intercurrent febrile condition 2. Previous reports of autoimmune disease 3. Concurrent chronic active viral hepatitis B or C or HIV 4. BMI>30 5. Persons with a history of anaphylaxis or serious reactions to a prior vaccination 6. Persons with known hypersensitivity to any of the vaccine components 7. Persons who have had a temperature >38 °C during the previous 72 hours 8. Persons who have had an acute respiratory infection during the last 7 days 9. Persons who have abnormal electrocardiogram (ECG) 10. Women who are pregnant or breast-feeding (women of child-bearing potential must have a negative pregnancy test at screening) 11. Have received any vaccination within the last month - Prior/Concomitant Therapy 12. Currently taking anti-inflammatory or immunosuppressive drugs 13. Currently taking antibiotics, steroids, phenytoin, chemotherapy, or other immunosuppressive drugs - Prior/Concurrent Clinical Study Experience 14. Persons who have participated in another clinical trial during the last month - Diagnostic assessments 15. Abnormal values of the hematologic and clinical chemistry parameters, as judged by the Investigator, including creatinine, AST, ALT (SGPT), bilirubin and alkaline phosphatase values above normal reference values 16. Positive autoantibodies (anti-nuclear antigens, rheumatoid factor) 17. Serum IgG and IgM lower or higher than the normal reference levels 18. Positive serology tests for hepatitis B or C with detectable hepatitis B HBsAg or DNA, or hepatitis C RNA 19. Positive HIV serology test |
Country | Name | City | State |
---|---|---|---|
Norway | Oslo University Hospital | Oslo |
Lead Sponsor | Collaborator |
---|---|
Oslo University Hospital |
Norway,
Grodeland G, Fredriksen AB, Loset GA, Vikse E, Fugger L, Bogen B. Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination. J Immunol. 2016 Nov 1;197(9):3575-3585. doi: 10.4049/jimmunol.1600893. Epub 2016 Sep 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Solicited adverse events following vaccination | Solicited injection site reactions: Redness, Swelling, Pain, Erythema, and Induration; Solicited systemic reactions: Fever, Sweating, Chill, Nausea, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, and Respiratory symptoms. | 10 days | |
Primary | Abnormalities in physical examination, vital signs, and clinical laboratory tests | Number of participants with aberrant results. | 6 months | |
Secondary | Changes in virus neutralization assay titres relative to baseline | geometric mean titres | 6 months | |
Secondary | Changes in anti-H7 antibody levels relative to baseline | seroconversion rates | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03999554 -
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
|
Phase 1 | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Completed |
NCT02487173 -
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
|
N/A | |
Completed |
NCT01701752 -
Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
|
Phase 1 | |
Enrolling by invitation |
NCT03207152 -
Biomarkers Predicting Infectivity in an Experimental Human Influenza Model
|
Phase 1 | |
Terminated |
NCT05567783 -
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
|
Phase 2 | |
Not yet recruiting |
NCT00987012 -
The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients
|
N/A | |
Not yet recruiting |
NCT05928507 -
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
|
||
Completed |
NCT03651544 -
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
|
Phase 1 | |
Completed |
NCT02623322 -
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
|
Phase 2 | |
Completed |
NCT03196661 -
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population
|
Phase 1 | |
Recruiting |
NCT06160531 -
Influenza Viral Challenge Study of CC-42344 in Healthy Participants
|
Phase 2 | |
Recruiting |
NCT06191393 -
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
|
N/A | |
Completed |
NCT06127108 -
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
|
N/A | |
Completed |
NCT05163730 -
Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
|
N/A | |
Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
Recruiting |
NCT04896853 -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
|
Phase 1 | |
Not yet recruiting |
NCT05787444 -
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
|
||
Completed |
NCT05354115 -
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
|
N/A | |
Completed |
NCT02014870 -
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
|
Phase 1 |